The Marshall Protocol Study Site Home

Search
   
Members

Calendar

Help

Home
Search by username
   Not logged in - Login | Register 
The Marshall Protocol Study Site > PROF. MARSHALL'S PERSPECTIVE > Prof. Marshall's Perspective > UK drug chief tells The Royal College that Observational studies should be encouraged


UK drug chief tells The Royal College that Observational studies should be encouraged
 Moderated by: Prof Trevor Marshall
 

New Topic

Reply

Print
AuthorPost
patrickburke
inactive member


Joined: Sun Jul 11th, 2004
Location: United Kingdom
Posts: 469
Status:  Offline
 Posted: Sat Oct 25th, 2008 17:23

Quote

Reply
http://news.bbc.co.uk/today/hi/today/newsid_7675000/7675335.stm

Even the experts know that its time for change.



____________________
Sarcoidosis/lungs; Ph1 May05; Ph2 Jun05; Ph3 Dec05; No ABX 2/08; No D tests; covered since 6/04; Noirs off 6/07; Min light avoidance| Pat's Story|
jrfoutin
Research Team


Joined: Mon Aug 8th, 2005
Location: Utah USA
Posts: 4923
Status:  Offline
 Posted: Sat Oct 25th, 2008 17:40

Quote

Reply
Interesting that the cost of the dominantly accepted study is identified in the dialog, even though scurried off as "another issue."

Still, the facade endpoints established by "do we have it right" discussions by the FDA have crept into study outcomes there, too, and I believe it was also discussed at the 2006 NORD conference.

Thank you for the link--Janet 



____________________
Sarcoidosis 125D61, MP10/05 ModP2 12/05 Ph2 6/06 Ph3 10/06, NoIRs limited outings covered, 2/08 25D6.2, 10/08 25D6.9
Prof Trevor Marshall
Foundation Staff


Joined: Fri Jul 9th, 2004
Location: Thousand Oaks, California USA
Posts: 15742
Status:  Offline
 Posted: Sat Oct 25th, 2008 17:58

Quote

Reply
Janet,
I think the cost being referred to is some limit on the maximum amount of medicine per person per year which is used as a guideline in the UK. I don't think it refers to study costs:)
 
Maybe somebody can clarify this for us...
 

patrickburke
inactive member


Joined: Sun Jul 11th, 2004
Location: United Kingdom
Posts: 469
Status:  Offline
 Posted: Sat Oct 25th, 2008 19:29

Quote

Reply
 Sir Micheal Rawlins,

"I think we spend too much attention on randomised controlled trials and we are not looking enough at observational trials"

 "In the real world the sort of randomised controlled trial we are very used to are not at all good at picking up safety problems"

"I think that this approach (observational) should be used more widely"

"I think sometimes it would mean that drugs were perhaps put on the market earlier than they would have been otherwise"



____________________
Sarcoidosis/lungs; Ph1 May05; Ph2 Jun05; Ph3 Dec05; No ABX 2/08; No D tests; covered since 6/04; Noirs off 6/07; Min light avoidance| Pat's Story|
Prof Trevor Marshall
Foundation Staff


Joined: Fri Jul 9th, 2004
Location: Thousand Oaks, California USA
Posts: 15742
Status:  Offline
 Posted: Sat Oct 25th, 2008 19:37

Quote

Reply
Patrick,
Actually his suggestion of a historical comparator is far more significant, for that is exactly what we did - we said that our comparison group was those patients (in the real world) not on the MP. That is a 'historical comparator', and is one of the most ethical, yet controversial, ways of conducting studies in serious diseases.
 

jrfoutin
Research Team


Joined: Mon Aug 8th, 2005
Location: Utah USA
Posts: 4923
Status:  Offline
 Posted: Thu Oct 30th, 2008 18:15

Quote

Reply
If I remember correctly (should check back maybe), I think it was mentioned and then dismissed as another issue. But cost of study types -- as well as more than one type of study -- per indication seems to have some sway on what might be put forth as reliable data so discussions like this one on the BBC are significant to note. 

I'm just glad that observational studies (and other types) are identified in the FDA critical path and that the UK is also identifying observational studies as important.

The Autoimmunity Research Foundation's work with regards to observational studies and the Web must certainly be a significant cornerstone example of ethical process, as well as reliable. Even if scientists aren't up on the impact of what the ARF has done with the Pathogenesis and Protocol, the Process and Platform have great historical significance.



____________________
Sarcoidosis 125D61, MP10/05 ModP2 12/05 Ph2 6/06 Ph3 10/06, NoIRs limited outings covered, 2/08 25D6.2, 10/08 25D6.9

 Current time is 18:37



* We can help you understand chronic disease, but only your physician is licensed to give you medical care *

Powered by WowBB 1.7 - Entire site Copyright © 2004-2020 Autoimmunity Research Foundation, All Rights Reserved
Click here to view our PRIVACY POLICY
Page processed in 0.2198 seconds (96% database + 4% PHP). 18 queries executed.